Point Biopharma Global Stock Fundamentals
PNTDelisted Stock | USD 9.06 0.10 1.09% |
POINT Biopharma Global fundamentals help investors to digest information that contributes to POINT Biopharma's financial success or failures. It also enables traders to predict the movement of POINT Stock. The fundamental analysis module provides a way to measure POINT Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to POINT Biopharma stock.
POINT |
POINT Biopharma Global Company Return On Equity Analysis
POINT Biopharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current POINT Biopharma Return On Equity | 0.26 |
Most of POINT Biopharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, POINT Biopharma Global is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, POINT Biopharma Global has a Return On Equity of 0.2633. This is 101.1% lower than that of the Biotechnology sector and 100.72% lower than that of the Health Care industry. The return on equity for all United States stocks is 184.94% lower than that of the firm.
POINT Biopharma Global Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining POINT Biopharma's current stock value. Our valuation model uses many indicators to compare POINT Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across POINT Biopharma competition to find correlations between indicators driving POINT Biopharma's intrinsic value. More Info.POINT Biopharma Global is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.64 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for POINT Biopharma Global is roughly 1.57 . Comparative valuation analysis is a catch-all technique that is used if you cannot value POINT Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.POINT Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses POINT Biopharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of POINT Biopharma could also be used in its relative valuation, which is a method of valuing POINT Biopharma by comparing valuation metrics of similar companies.POINT Biopharma is currently under evaluation in return on equity category among its peers.
POINT Fundamentals
Return On Equity | 0.26 | |||
Return On Asset | 0.17 | |||
Profit Margin | 0.40 % | |||
Operating Margin | (10.62) % | |||
Current Valuation | 1 B | |||
Shares Outstanding | 106.57 M | |||
Shares Owned By Insiders | 14.97 % | |||
Shares Owned By Institutions | 48.91 % | |||
Number Of Shares Shorted | 2.64 M | |||
Price To Book | 3.13 X | |||
Price To Sales | 5.45 X | |||
Revenue | 226.58 M | |||
EBITDA | 127.32 M | |||
Net Income | 98.29 M | |||
Cash And Equivalents | 199.43 M | |||
Cash Per Share | 2.21 X | |||
Total Debt | 3.56 M | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 10.90 X | |||
Book Value Per Share | 4.01 X | |||
Cash Flow From Operations | 183.52 M | |||
Short Ratio | 0.98 X | |||
Earnings Per Share | 1.10 X | |||
Target Price | 12.5 | |||
Number Of Employees | 129 | |||
Beta | -0.003 | |||
Market Capitalization | 1.33 B | |||
Total Asset | 578.32 M | |||
Retained Earnings | 39.01 M | |||
Working Capital | 451.08 M | |||
Net Asset | 578.32 M |
About POINT Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze POINT Biopharma Global's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of POINT Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of POINT Biopharma Global based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. Point Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
Commodity Directory Find actively traded commodities issued by global exchanges | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |